Dr. Lal PathLabs (LALPATHLAB) Q2 24/25 earnings summary

Executive summary

• Maintained strong market position in a fragmented diagnostics industry through brand strength, service quality, and network expansion, especially into Tier 3 and 4 regions, with 35% of revenue from these regions in FY24.

• Achieved highest-ever quarterly revenue of INR 660 crore in Q2 FY25, up 9.8% year-over-year, and H1 FY25 revenue of INR 1,262 crore, up 10.5% year-over-year.

• PAT grew 18.1% year-over-year in Q2 FY25 to INR 131 crore, with robust profitability driven by operational leverage and cost optimization.

• Focused on digital integration, home diagnostics, and affordable services to drive patient volume and efficiency without price hikes.

• Celebrated 75 years of operations; announced leadership transition with the Managing Director moving to an advisory role in March 2025.

Financial highlights

• Q2 FY25 revenue grew 9.8% year-over-year to INR 660 crore; H1 FY25 revenue up 10.5% to INR 1,262 crore.

• Q2 FY25 EBITDA rose 13.9% to INR 202 crore (margin 30.7%); PAT increased 18.1% to INR 131 crore (margin 19.8%).

• Revenue per patient for Q2 FY25 was INR 844, up 5.7% year-over-year; tests per patient increased to 2.94.

• Net cash as of September 30, 2024, stood at INR 1,095 crore; DSO at 25 days; negative working capital of 22 days.

• Board approved a second interim dividend of INR 6 per share for FY25.

Outlook and guidance

• Revenue growth guidance maintained at equal to or better than last year’s 10.4%; H1 FY25 delivered 10.5%.

• No price increases planned for FY25; focus remains on volume growth, network expansion, and digital infrastructure.

• Margin guidance is for stability or slight improvement over last year, with Q2 margins not indicative of full-year performance.

• On track to open 15-20 new labs and add ~800 collection centers across both brands in FY25.

• Continued emphasis on operational efficiency, volume growth, and leveraging technology for patient experience.